公开(公告)号：US20240309016A1

公开(公告)日：2024-09-19

申请号：US18606857

申请日：2024-03-15

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Mitsunori KONO ,  Yusuke SASAKI ,  Yuya OGURO ,  Zenichi IKEDA ,  Osamu KUBO ,  Masaki SETO ,  Toru YAMASHITA ,  Makoto KAMATA ,  Kenjiro SATO ,  Matthew Thomas REYNOLDS ,  Kazuaki TAKAMI ,  Asato KINA ,  Takafumi YUKAWA ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Keiko KAKEGAWA ,  Takuto KOJIMA ,  Florian PÜNNER ,  Masataka MURAKAMI ,  Takahiko TANIGUCHI ,  Tatsuki KOIKE ,  Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Yasushi HATTORI ,  Eiji KIMURA ,  Martin Alexander PAWLICZEK ,  Marilena PIRA ,  Shuhei IKEDA ,  Noriyuki TEZUKA ,  Yoshikazu WATANABE ,  Kevin CURRAN ,  Nicolle DOERING ,  Maria HOPKINS ,  Ben JOHNSON ,  Andre KIRYANOV ,  Jon LAM ,  Sean MURPHY ,  Natasha O'ROURKE ,  Holly REICHARD ,  Paul TANIS ,  Yunlong ZHANG

IPC分类号： C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

CPC分类号： C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20240317765A1

公开(公告)日：2024-09-26

申请号：US18629703

申请日：2024-04-08

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Yasushi HATTORI ,  Marilena PIRA ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Eiji KIMURA ,  Norihito TOKUNAGA ,  Shuhei IKEDA ,  Martin Alexander PAWLICZEK ,  Noriyuki TEZUKA ,  Yasutaka HOASHI ,  Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Tatsuki KOIKE

IPC分类号： C07D487/04 ,  A61P25/00 ,  C07D413/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61P25/00 ,  C07D413/04 ,  C07D519/00

摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20240174677A1

公开(公告)日：2024-05-30

申请号：US18497602

申请日：2023-10-30

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Yasushi HATTORI ,  Marilena PIRA ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Eiji KIMURA ,  Norihito TOKUNAGA ,  Shuhei IKEDA ,  Martin Alexander PAWLICZEK ,  Noriyuki TEZUKA ,  Yasutaka HOASHI ,  Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Tatsuki KOIKE

IPC分类号： C07D487/04 ,  A61P25/00 ,  C07D413/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61P25/00 ,  C07D413/04 ,  C07D519/00

摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20230322683A1

公开(公告)日：2023-10-12

申请号：US17766400

申请日：2020-10-15

申请人： Takeda Pharmaceutical Company Limited

发明人： Masashi TOYOFUKU ,  Yoshiteru ITO ,  Marilena PIRA ,  Takahiro SUGIMOTO

IPC分类号： C07D231/56 ,  C07D405/12 ,  C07D471/04 ,  C07D498/04 ,  A61P25/28

CPC分类号： C07D231/56 ,  C07D405/12 ,  C07D471/04 ,  C07D498/04 ,  A61P25/28

摘要： The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20230037557A1

公开(公告)日：2023-02-09

申请号：US17780125

申请日：2020-11-26

申请人： Takeda Pharmaceutical Company Limited

发明人： Yoshiteru ITO ,  Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Tatsuki KOIKE ,  Norihito TOKUNAGA ,  Eiji KIMURA ,  Alexander Martin PAWLICZEK ,  Marilena PIRA ,  Javier MIGUELEZ-RAMOS

IPC分类号： C07D471/04 ,  A61P25/00

摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.